Neues vorbeugendes Migränemedikament Erenumab (Aimovig) durch FDA zugelassen – Schmerzklinik Kiel
Vorläufige Gespräche: Horizon-Aktie schnellt hoch: Horizon Therapeutics spricht mit Amgen, Janssen und Sanofi über mögliches
Amgen Aktie Analyse | AlleAktien
Top Research Reports for Novo Nordisk, Amgen & ADP
Amgen Pipeline
Amgen Weighs In to Chase Rival Obesity Drugs From Novo Nordisk and Eli Lilly - MedCity News
Amgen's Lumakras off to a strong start toward analyst's blockbuster predictions pegged to combo potential | Fierce Pharma
Products | Amgen
Amgen-partnered researchers treat diabetes in mice by silencing IL-2's inflammatory power | Fierce Biotech
CME-Fortbildung - Diabetes mellitus und Herzinsuffizienz – tödliches Duo • diabetologie-online
Angiotensin II als Medikament | PZ – Pharmazeutische Zeitung
Kiffen könnte Typ-2-Diabetes verzögern
Products | Amgen
Amgen's AMG-133 shows potential in competing with GLP-1RA obesity therapies - Pharmaceutical Technology
Array BioPharma and Amgen Partner in Type 2 Diabetes| Amgen
LUMAKRAS (Sotorasib) for the Treatment of Non-Small Cell Lung Cancer
Amgen - Wikipedia
Herz-Kreislauf-Erkrankungen: Risikofaktor LDL-Cholesterin im Fokus | Presseportal
Amgen's report projects major growth for biosimilars in the U.S.
ASCO GU: Amgen's Lumakras posts encouraging results in pancreatic cancer, though not as dazzling as Mirati rival | Fierce Pharma
J&J, Amgen, Regeneron Drugs Likely to Face Medicare Negotiation (1)
